Shareholder Sues Hims After Partnership That Allowed Compounded Semaglutide Ends
SAN FRANCISCO — Hims & Hers Health Inc., a telehealth company that touted a collaboration with Novo Nordisk Inc. that would allow it to sell compounded semaglutide products, was hit with...To view the full article, register now.
Already a subscriber? Click here to view full article